Melanotan-2: Chemical Properties
$25.20 · COA do lote publicado · Água BAC grátis + frete grátis nos EUA · Despacho no mesmo dia antes das 14h ET · APENAS PARA USO EM PESQUISA
Comprar peptídeo Melanotan 2 10mg (MT-2)24 Citacoes PubMedRevisado por EspecialistasUltima Revisao: fevereiro de 2026
Propriedades Quimicas
| Molecular Formula | C₅₀H₆₉N₁₅O₉ |
| Molecular Weight | 1024.18 Da |
| CAS Number | 121062-08-6 |
| PubChem CID | 92432 |
| Sequence | Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ |
| Structure | Cyclic heptapeptide; lactam bridge (Asp-Lys); Ac-Nle replaces α-MSH Ser-Tyr-Ser-Met; D-Phe replaces L-Phe |
| Parent Molecule | α-MSH (alpha-melanocyte-stimulating hormone) |
| InChI Key | JDKLPDJLXHXHNV-MFVUMRCOSA-N |
| Half-Life (Human) | ~1–2 hours (aprimorou vs α-MSH by cyclic structure) |
| BBB Penetration | Yes (diferentemente de Melanotan I) |
| Receptor Profile | Non-selective MCR agonist: MC1R, MC3R (Ki 1.3 nM), MC4R (Ki 1.1 nM), MC5R; NO activity at MC2R |
Identificadores
| Purity Standard | ≥98% by RP-HPLC |
| Identity Confirmation | ESI-MS m/z 512 [M+2H]²⁺ and 1024 [M+H]⁺; LC-UV-MS/MS validated |
| Counter-Ion | Não informado no certificado de lote publicado |
| Synonyms | MT-II, MT2, Melanotan-II, Barbie drug/peptide |
| Detection Methods | HPLC, ESI-MS, LC-UV-MS/MS, urine/blood MS (toxicology) |
Editorial Research Note
“Resumo da Pesquisa Pre-clinica Key Preclinical Studies EstudoModeloPrincipais AchadosRef Côté et al.”
Referencias
- Dorr RT, Lines R, Levine N, et al. Life Sciences. 1996;58(20):1777-1784.
- Hadley ME, Dorr RT. Peptides. 2006;27(4):921-930.
- Wessells H, Fuciarelli K, Hansen J, et al. The Journal of Urology. 1998;160(2):389-393.
- FDA Warning Letters regarding unauthorized marketing of Melanotan products.
- Vemulapalli R, Kurowski S, Salisbury B, et al. Activation of central melanocortin receptors by MT-II aumenta cavernosal pressure in rabbits pelo(a) neuronal release of NO. British Journal of Pharmacology. 2001;134(8):1705-1710.
- Côté I, et al. Activation do(a) central melanocortin system chronically reduz body mass sem the necessity of longo prazo caloric restriction. Canadian Journal of Physiology and Pharmacology. 2017.
- Ford CL, McDonough AA, Horie K, Young LJ. Melanocortin agonism in a social context ativa seletivamente nucleus accumbens in an oxytocin-dependent manner. Neuropharmacology. 2024;247:109848.
- Jain S, Panyutin A, Liu N, et al. Melanotan II causes hypothermia in mice by ativacao of mast cells and estimulacao of histamine 1 receptors. American Journal of Physiology-Endocrinology and Metabolism. 2018;315(3):E357-E366.
- Wessells H, Levine N, Hadley ME, Dorr RT, Hruby VJ. Urology. 2000;56(4):641-646.
- Eliason NL, Martin L, Low MJ, Sharpe AL. Melanocortin agonista do receptor melanotan-II microinjected no(a) nucleus accumbens diminui appetitive and consumptive responding for food. Neuropeptides. 2022;96:102289.
- Minakova E, Lang J, Medel-Matus JS, et al. PLoS ONE. 2019;14(1):e0210389.
- Ter Laak MP, et al. Melanotan II promove periferico(a) regeneracao nervosa in a rat sciatic nerve crush model. 2003.
- Evans-Brown M, Dawson RT, Chandler MD, McVeigh J. Use of melanotan I and II no(a) general population. BMJ. 2009;338:b566.
- Wu JC, Tsai HE, Hsiao YH, et al. International Journal of Molecular Sciences. 2020;21(2):681.
- Dreyer BA, Amer T, Fraser M. BMJ Case Reports. 2019;12(2):e227644.
- Nelson ME, Bryant SM, Aks SE. Clinical Toxicology. 2012;50(10):1169-1173.
- Peters B, Hadimeri H, Wahlberg R, Afghahi H. CEN Case Reports. 2020;9(2):159-161.
- Sivyer GW. Dermatology Practical & Conceptual. 2012.
- Ryakhovsky VV, Khachiyan GA, Kosovova NF, et al. The primeiro(a) preparative solution phase synthesis of melanotan II. Beilstein Journal of Organic Chemistry. 2008;4:39.
- Hjuler KF, Lorentzen HF. Melanoma associado(a) com the use of melanotan-II. Dermatology. 2014;228(1):34-36.
- Giuliano F, Clement P, Droupy S, et al. Neuroscience. 2006;138(1):293-301.
- Li G, Zhang Y, Wilsey JT, Scarpace PJ. Unabated anorexic and aprimorou thermogenic responses to melanotan II in diet-induziu ratos obesos. Journal of Endocrinology. 2004;182(1):123-132.
- King SH, et al. Current Topics in Medicinal Chemistry. 2007;7(11):1111-1119.
- Wessells H, Levine N, Hadley ME, Dorr RT, Hruby VJ. International Journal of Impotence Research. 2000;12(Suppl 4):S74-S79.
Perguntas de Pesquisa Relacionadas
Related research
Browse all research guides in the Peptide Research Library →Deseja a revisao completa da pesquisa?
Comprar peptídeo Melanotan 2 10mg (MT-2)→APENAS PARA USO EM PESQUISA
Este conteudo e fornecido apenas para fins educacionais e informativos. Os produtos sao fornecidos apenas para estudos in vitro e nao sao medicamentos, drogas ou suplementos. Nao aprovado pela FDA para prevenir, tratar ou curar qualquer condicao.
